A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells
Authors:
Open Access
- 27 May 2013
- journal article
- research article
- Published by Spandidos Publications in Oncology Reports
- Vol. 30 (2) , 863-869
Abstract
Lung cancer is the leading cause of cancer-related mortality in the world, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases. Since more than 60% of NSCLC cases express the epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitors are used to treat NSCLC. However, due to the acquired resistance associated with EGFR-targeted therapy, other strategies for the treatment of NSCLC are urgently needed. Therefore, we investigated the anticancer effects of a novel phosphatidylinositol 3-kinase α (PI3Kα) inhibitor, HS-173, in human NSCLC cell lines. HS-173 demonstrated anti-proliferative effects in NSCLC cells and effectively inhibited the PI3K signaling pathway in a dose‑dependent manner. In addition, it induced cell cycle arrest at G2/M phase as well as apoptosis. Taken together, our results demonstrate that HS-173 exhibits anticancer activities, including the induction of apoptosis, by blocking the PI3K/Akt/mTOR pathway in human NSCLC cell lines. We, therefore, suggest that this novel drug could potentially be used for targeted NSCLC therapy.Keywords
This publication has 29 references indexed in Scilit:
- The emerging mechanisms of isoform-specific PI3K signallingNature Reviews Molecular Cell Biology, 2010
- Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapyCancer and Metastasis Reviews, 2010
- Targeting PI3K signalling in cancer: opportunities, challenges and limitationsNature Reviews Cancer, 2009
- Differences in Practice Patterns and Costs between Small Cell and Non-Small Cell Lung Cancer Patients in JapanThe Tohoku Journal of Experimental Medicine, 2009
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell linesProceedings of the National Academy of Sciences of the United States of America, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLOS Medicine, 2005
- Targeting the PI3K-Akt pathway in human cancerCancer Cell, 2003
- The Phosphoinositide 3-Kinase PathwayScience, 2002
- Lung cancer heterogeneity: A blinded and randomized study of 100 consecutive casesHuman Pathology, 1985